A Leading Pharmaceutical Brand Increased Adherence 29% YoY with Swoop’s Patented Predictive Non-Adherence Audiences
With an increased incidence in substance use disorders (SUDs), a MAT therapy wanted to increase adherence within its patient population to drive positive patient outcomes. Leveraging Swoop’s patented predictive technology, the brand was able to accurately identify patients most likely to become non-adherent and activate them programmatically across premium inventory.
Help patients start and stay on therapy programs prescribed by their doctors
NimbleRx, a Swoop Company, connects prescription fulfillment capabilities with commercial intelligence to turn real-world signals into action, improve medication adherence, and reduce treatment delays.
Adding Nimble advances Swoop’s position as the only integrated ecosystem built to connect patients and HCPs with the right information to improve health outcomes.
Preventing a chronic condition or progression of a disease takes concerted effort from patients, payers, pharma brands, and physicians. Is it possible to truly move from sick care to health care?
It’s time to reassess the knee-jerk reaction of suppressing entire states from marketing campaigns and consider more sophisticated, compliant approaches to audience targeting.